RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

This study is testing a new drug called RMC-5552 for people with glioblastoma (a highly aggressive brain cancer) that has come back after standard treatment. The drug targets a specific protein pathway (mTOR) that drives tumor growth. **You may be eligible if:** - You have been diagnosed with recurrent glioblastoma (1st, 2nd, or 3rd recurrence) - Your tumor shows measurable disease on brain imaging - You have already received standard treatment including surgery and radiation - You are well enough to participate (ECOG performance status 0–2) - You are 18 or older **You may NOT be eligible if:** - You have significant uncontrolled medical conditions (heart, liver, lung, kidney problems) - You are pregnant - You have uncontrolled infections - You have had recent major surgery or are on certain medications that could interact with the study drug Talk to your doctor to see if this trial is right for you.